CompletedPhase 2NCT02854839

A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma

Studying Combined hepatocellular carcinoma and cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
GC Cell Corporation
Principal Investigator
Jung Hwan Yoon, M.D., Ph.D.
Seoul National University Hospital
Intervention
MG4101(biological)
Enrollment
78 enrolled
Eligibility
18-80 years · All sexes
Timeline
20162019

Study locations (6)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02854839 on ClinicalTrials.gov

Other trials for Combined hepatocellular carcinoma and cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Combined hepatocellular carcinoma and cholangiocarcinoma

← Back to all trials